• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
 
  • Details
  • Full
Options
2021
Journal Article
Title

A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection

Abstract
SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic, in which acute respiratory infections are associated with high socio-economic burden. We applied high-content screening to a well-defined collection of 5632 compounds including 3488 that have undergone previous clinical investigations across 600 indications. The compounds were screened by microscopy for their ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2. The primary screen identified 258 hits that inhibited cytopathicity by more than 75%, most of which were not previously known to be active against SARS-CoV-2 in vitro. These compounds were tested in an eight-point dose response screen using the same image-based cytopathicity readout. For the 67 most active molecules, cytotoxicity data were generated to confirm activity against SARS-CoV-2. We verified the ability of known inhibitors camostat, nafamostat, lopinavir, mefloquine, papaverine and cetylpyridinium to reduce the cytopathic effects of SARS-CoV-2, providing confidence in the validity of the assay. The high-content screening data are suitable for reanalysis across numerous drug classes and indications and may yield additional insights into SARS-CoV-2 mechanisms and potential therapeutic strategies.
Author(s)
Ellinger, B.
Bojkova, D.
Zaliani, A.
Cinatl, J.
Claussen, C.
Westhaus, S.
Keminer, O.
Reinshagen, J.
Kuzikov, M.
Wolf, M.
Geisslinger, G.
Gribbon, P.
Ciesek, S.
Journal
Scientific data  
Open Access
DOI
10.1038/s41597-021-00848-4
Additional full text version
Landing Page
Language
English
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024